Key Highlights

● Acurx Pharmaceuticals says regulators have aligned on the design of pivotal phase 3 trials for its oral antibiotic ibezapolstat in C. difficile infection, while the clinical-stage company continues to raise cash through dilutive at-the-market offerings to fund the work.

● Acurx reported $9.25 million in cash as of March 31, 2026, up from $7.56 million at year-end 2025, aided by roughly $3.1 million drawn under an equity facility.

● Acurx has explicitly disclosed going-concern doubt, and its share count has grown substantially through dilutive offerings even after a 2025 reverse split.

● Investors should watch for confirmed initiation of patient dosing in the Phase 3 acute-CDI trials.

Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP), a clinical-stage biopharmaceutical company based in Staten Island, New York, is advancing ibezapolstat, an oral antibiotic candidate designed to treat Clostridioides difficile infection (CDI) while sparing the beneficial bacteria of the gut microbiome. The company says it has reached agreement with the FDA and the European Medicines Agency on the design of pivotal phase 3 trials for the drug and is separately preparing a smaller pilot study in patients with multiply-recurrent CDI, a harder-to-treat population. Acurx remains pre-revenue, funding both programs through small offerings, an equity line of credit, and registered direct placements, and its own filings disclose recurring doubt about its ability to fund operations without additional capital.

What happened

In a March 2026 announcement, Acurx said it had received "final EMA and FDA agreement" on pivotal phase 3 trial design elements for ibezapolstat in CDI, including patient population, endpoints, and safety database requirements, and described a roadmap toward a U.S. new drug application and EU marketing authorization application if the trials succeed. Alongside that update, the company disclosed a new initiative: an open-label pilot study of up to 20 patients with multiply-recurrent CDI (at least three episodes within 12 months), intended to precede a later phase 3 registration trial in that population, potentially under the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs. Its first-quarter 2026 Form 10-Q said the rCDI pilot was being readied for startup, with first patient enrollment anticipated later in 2026. The company also presented microbiome data on ibezapolstat at scientific conferences this spring and closed a registered direct equity offering of up to $7.1 million in mid-April 2026.

Why the development matters

Regulatory alignment on trial design removes one source of uncertainty for a small company attempting a costly, multi-country phase 3 program, clearing a hurdle Acurx has pursued for years. But "final agreement on trial design" is not a funded, enrolling phase 3 trial: Acurx has not disclosed that either of the two roughly 475-patient acute-CDI phase 3 trials it previously described has begun dosing patients, nor a committed budget or partner to fund a program of that scale. The parallel rCDI pilot appears designed to generate supportive data and open a more targeted pathway, but it, too, remains early-stage and unfunded at scale. For investors, the near-term catalyst is less "phase 3 results" and more whether Acurx can convert regulatory clarity into a financed trial before its cash position and Nasdaq standing come under renewed pressure.

Company and product background

Ibezapolstat is a first-in-class inhibitor of bacterial DNA polymerase IIIC, an enzyme essential to Gram-positive bacterial DNA replication, distinguishing its mechanism from existing CDI antibiotics such as vancomycin and fidaxomicin. The company reports a completed phase 1 study comparing ibezapolstat with oral vancomycin, a phase 2a study with high reported cure rates, and a phase 2b non-inferiority trial (32 patients) versus vancomycin with topline results in late 2023; its most recent annual report cites a 96% (25 of 26 patients) pooled phase 2 cure rate, differing modestly from the "100%" cited for phase 2a alone, a discrepancy worth noting across company materials. Ibezapolstat holds FDA Qualified Infectious Disease Product and Fast Track designations (2018, 2019) and an EMA small and medium-sized enterprise designation (2024). Acurx has not announced a bitcoin or digital-asset treasury policy: a full-text search of its SEC filings and press releases from 2024 through July 2026 found no reference to bitcoin, so characterizing Acurx as having adopted a bitcoin treasury strategy is not corroborated by its own disclosures.

Financial position

Acurx reported $9.25 million in cash as of March 31, 2026, up from $7.56 million at year-end 2025 and $3.71 million a year earlier, aided by roughly $3.1 million drawn under an equity line of credit and the $7.1 million offering that closed in mid-April 2026. Net losses have narrowed: $7.97 million for full-year 2025 versus $14.10 million in 2024, and $1.68 million in the first quarter of 2026 versus $2.15 million a year earlier, with R&D spending of $341,468 (down from $598,798) and G&A costs of $1.37 million (down from $1.58 million). Shares outstanding have risen sharply amid the fundraising, from 2.35 million at year-end 2025 to 3.39 million at March 31 and 4.30 million by mid-May, reflecting continued dilution after a 2025 reverse stock split. Acurx's own filing states that cash "will not be sufficient to meet its anticipated cash requirements for at least 12 months" and discloses substantial doubt about its ability to continue as a going concern.

Bull case

Ibezapolstat's microbiome-sparing mechanism addresses a recognized unmet need in CDI, where standard antibiotics can worsen the dysbiosis that drives recurrence. Regulatory alignment with the FDA and EMA on phase 3 design removes a key procedural uncertainty, and Fast Track and QIDP designations offer potential expedited-review and exclusivity benefits. Management has also repeatedly raised incremental capital while narrowing quarterly losses and building cash above $9 million.

Risk case

Acurx has explicitly disclosed going-concern doubt, and its share count has grown substantially through dilutive offerings even after a 2025 reverse split, a pattern often tied to sustained share-price pressure. Neither the acute-CDI phase 3 trials nor the rCDI pilot has a disclosed enrollment start date with patients dosed, and the company has not disclosed the total estimated cost of the phase 3 program or committed funding for it. As a single-product, pre-revenue company, Acurx faces execution, financing, and regulatory risk common to small-cap clinical-stage biotechs, and any setback could pressure its cash runway and Nasdaq listing standing further.

What investors should watch next

Investors should watch for: confirmed initiation of patient dosing in the phase 3 acute-CDI trials or the rCDI pilot; disclosure of a financing plan or non-dilutive grant sized to fund a multi-country phase 3 program; second-quarter 2026 results, expected around the already-announced August 14, 2026 call; further at-the-market or registered direct offerings and their effect on share count; and any Nasdaq listing-compliance correspondence.

Conclusion

Acurx has cleared a meaningful regulatory-design milestone for ibezapolstat and continues to generate microbiome data supporting its antibiotic platform, but the company remains pre-revenue, has not disclosed a funded and enrolling phase 3 trial, and has explicitly flagged going-concern risk in its own SEC filings. Investors should weigh the scientific and regulatory progress against the financing gap and dilution history without assuming either the trials or the funding will proceed on any particular timeline.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.